Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review.
Addressing Clinical Inertia in Type 2 Diabetes Mellitus: A Review.
复制标题
DOI：
10.1007/s12325-018-0819-5
复制
发表时间：
2018-11
影响因子：
3.8
通讯作者：
Quiñones M
中科院分区：
文献类型：
--
作者：
Okemah J;Peng J;Quiñones M
目前2型糖尿病（T2D）的流行是一个重大的全球和国家健康问题。在全球范围内，糖尿病的患病率在1980年至2014年间翻了一番。2014年，世界卫生组织估计全球有4.22亿成年人患有糖尿病。在美国，到2050年，被诊断患有T2D的人数估计将增加到7000多万，给美国医疗保健系统带来巨大压力。实现血糖控制被广泛认为是T2D治疗的关键目标，对于减少糖尿病相关并发症（如心血管疾病、神经病变、视网膜病变和肾病）的发生和进展至关重要。尽管抗高血糖药物和循证治疗指南的可用性增加，但未能实现血糖目标的T2D患者比例继续上升。一个主要原因是尽管血糖控制不佳，但治疗强化延迟，称为临床或治疗惰性。临床惰性延长了患者高血糖的持续时间，这随后使他们面临糖尿病相关并发症的风险增加和预期寿命缩短。临床惰性是患者、医疗保健提供者和医疗保健系统障碍之间复杂的相互作用的结果，这些障碍需要一起解决，而不是作为单独的实体。在这篇文章中，我们提供了一个概述的临床惰性在T2D的临床管理，并提供建议，克服方面可能有负面影响的病人护理。资金来源：Sanofi US，Inc.
The current epidemic of type 2 diabetes (T2D) represents a significant global and national health concern. Globally, the prevalence of diabetes has doubled between 1980 and 2014. In 2014 the World Health Organization estimated that there were 422 million adults living with diabetes worldwide. In the USA, the number of people diagnosed with T2D is estimated to increase to over 70 million by 2050, putting an immense strain on the US healthcare system. Achieving glycemic control is widely acknowledged as the key goal of treatment in T2D and is critical for reducing the onset and progression of diabetes-related complications such as cardiovascular diseases, neuropathies, retinopathies, and nephropathies. Despite the increase in the availability of antihyperglycemic medications and evidence-based treatment guidelines, the proportion of people with T2D who fail to achieve glycemic goals continues to rise. One major contributor is a delay in treatment intensification despite suboptimal glycemic control, referred to as clinical or therapeutic inertia. Clinical inertia prolongs the duration of patients’ hyperglycemia which subsequently puts them at increased risk of diabetes-associated complications and reduced life expectancy. Clinical inertia results from a complex interaction between patient, healthcare providers, and healthcare system barriers that need to be addressed together, rather than as separate entities. In this article we provide an overview of clinical inertia in the clinical management of T2D and provide suggestions for overcoming aspects that may have a negative impact on patient care. Funding: Sanofi US, Inc.
登录
查看更多内容
影响因子：
2.4
作者：
Blonde L;Aschner P;Bailey C;Ji L;Leiter LA;Matthaei S;Global Partnership for Effective Diabetes Management
通讯作者：
Global Partnership for Effective Diabetes Management
DOI：
10.1900/rds.2014.11.138
发表时间：
2014-01-01
期刊：
The review of diabetic studies : RDS
影响因子：
--
作者：
Arnold, Luke W;Wang, Zhiqiang
通讯作者：
Wang, Zhiqiang
影响因子：
16.2
作者：
Buse, John B.;Vilsboll, Tina;Rodbard, Helena W.
通讯作者：
Rodbard, Helena W.
影响因子：
3.8
作者：
Blonde, Lawrence;Meneghini, Luigi;McCrimmon, Rory J.
通讯作者：
McCrimmon, Rory J.
影响因子：
16.2
作者：
Aroda, Vanita R.;Rosenstock, Julio;Bergenstal, Richard M.
通讯作者：
Bergenstal, Richard M.